Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab.

Yonezawa, Atsushi; Chester, Cariad; Rajasekaran, Narendiran; Kohrt, Holbrook E

Yonezawa, Atsushi; Chester, Cariad; Rajasekaran, Narendiran; Kohrt, Holbrook E.

Afiliación

Yonezawa A; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA; Department of Clinical Pharmacology & Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, Japan.
Chester C; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA.
Rajasekaran N; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
Kohrt HE; Division of Oncology, Department of Medicine, Stanford University, CCSR Building, Room 1110, Stanford, CA 94305, USA. kohrt@stanford.edu.

Chin Clin Oncol ; 5(1): 5, 2016 Feb.

Article en En | MEDLINE | ID: mdl-26932429

Asunto(s)

Anticuerpos Monoclonales/uso terapéutico; Citotoxicidad Celular Dependiente de Anticuerpos/inmunología; Sistema Inmunológico/inmunología; Inmunoterapia; Neoplasias/terapia; Miembro 9 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/inmunología; Animales; Citotoxicidad Celular Dependiente de Anticuerpos/efectos de los fármacos; Ensayos Clínicos como Asunto; Humanos; Sistema Inmunológico/efectos de los fármacos; Neoplasias/inmunología; Pronóstico

Palabras clave

CD137 is a costimulatory receptor that belongs to the tumor necrosis factor receptor (TNFR) superfamily. CD137 is expressed on T cell, activated NK cells and other immune cells. We recently showed that an agonistic anti-CD137 mAb activates NK cells, resul; Efficacy of anti-CD137 mAb was examined by in vitro and in vivo experiments. Clinical trials of anti-CD137 mAb are also on-going.; Monoclonal antibodies are an invaluable therapeutic class when it comes to cancer therapy. One of the primary mechanisms of anti-tumor activity of monoclonal antibodies is antibody dependent cell-mediated cytotoxicity (ADCC) mediated by natural killer (NK; We discuss some of the promising strategies that could potentially enhance ADCC with anti-CD137 mAbs.

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Miembro 9 de la Superfamilia de Receptores de Factores de Necrosis Tumoral / Sistema Inmunológico / Inmunoterapia / Anticuerpos Monoclonales / Citotoxicidad Celular Dependiente de Anticuerpos / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Chin Clin Oncol Año: 2016 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google